PRTAライブシグナル | Getagraph.comで利益を最大化

買う 107768 min ago

@ $27.01

発行日: 15 2月 2024 @ 05:42

リターン: -19.84%

前回のシグナル: 2月 14 - 23:30

前回のシグナル: 売る

リターン: -1.57 %

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:50):

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States...

Stats
本日の出来高	182 068
平均出来高	656 330
時価総額	1.16B
EPS	$0 ( 2024-02-15 )
次の収益日	( $-1.210 ) 2024-05-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-7.84
ATR14	$0.0500 (0.23%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-01	Ford David A	Buy	85 000	Stock Option (Right to Buy)
2024-03-01	Ford David A	Buy	0
2024-02-27	Zago Wagner M.	Buy	85 000	Stock Option (Right to Buy)
2024-02-27	Walker Karin L	Buy	54 000	Stock Option (Right to Buy)
2024-02-27	Smith Brandon S.	Buy	85 000	Stock Option (Right to Buy)

INSIDER POWER
77.71
Last 98 transactions
Buy: 1 184 000 \| Sell: 192 000

ボリューム相関

長: -0.08 (neutral)

短: -0.17 (neutral)

Signal:(42.849) Neutral

Prothena Corporation PLC 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Prothena Corporation PLC 相関 - 通貨/商品

-0.79
( moderate negative )

-0.73
( moderate negative )

0.00
( neutral )

-0.70
( moderate negative )

-0.06
( neutral )

0.06
( neutral )

Prothena Corporation PLC 財務諸表

Annual	2023
収益:	$91.37M
総利益:	$82.96M (90.79 %)
EPS:	$-2.76

FY	2023
収益:	$91.37M
総利益:	$82.96M (90.79 %)
EPS:	$-2.76

FY	2022
収益:	$53.91M
総利益:	$47.16M (87.49 %)
EPS:	$-2.47

FY	2021
収益:	$200.58M
総利益:	$0.00 (0.00 %)
EPS:	$1.510

Financial Reports:

No articles found.

Prothena Corporation PLC

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.

リアルタイムの更新： Prothena Corporation PLC [PRTA]

Upcoming Earnings Alert